Lithium Carbonate ER
Roxane Laboratories Inc (Columbus,Ohio) recently announced the approval ofLithium Carbonate Extended ReleaseTablets USP, 450 mg. This product is ABratedto GlaxoSmithKline?s Eskalith CR(lithium carbonate) 450 mg. LithiumCarbonate Extended Release Tablets areindicated for the treatment of manicepisodes of manic?depressive illness.Maintenance therapy prevents or diminishesthe intensity of subsequentepisodes in those manic?depressivepatients with a history of mania. Thetablets may produce a normalization ofsymptomatology within 1 to 3 weeks. Formore information, visit www.roxane.com.